MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Fate Therapeutics Long-Term Debt 2011-2026 | FATE
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Fate Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.3 M | 77.8 M | 97.4 M | 104 M | 109 M | - | - | 12.4 M | 14.8 M | 2.5 M | 10.7 M | 18.1 M | - | 1.73 M | 3.59 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 1.73 M | 43.8 M |
Quarterly Long-Term Debt Fate Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.5 M | 75.7 M | 76.8 M | 77.8 M | 92.1 M | 93.9 M | - | 97.4 M | 99 M | 101 M | 102 M | 104 M | 105 M | - | 108 M | 109 M | 104 M | 105 M | 107 M | 93.9 M | 93.9 M | 93.9 M | 93.9 M | 25.2 M | 25.2 M | 9.47 M | 11 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 1.75 M | 250 K | - | - | 1.73 M | 1.73 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 250 K | 47.3 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
38.2 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
1.13 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
620 M | $ 21.65 | 1.12 % | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
38 K | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
130 K | $ 0.9 | -0.18 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
173 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
42 M | $ 22.3 | 1.55 % | $ 3.7 B | USA |
 |
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
171 K | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
85 K | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
1.1 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
1.82 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
2.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
1.29 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 102.06 | -3.22 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
45 M | $ 4.1 | 0.49 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
108 M | $ 23.42 | 0.69 % | $ 2.98 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
66.8 M | $ 1.42 | -1.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
17.5 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
188 K | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
962 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
37.7 M | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
2.21 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
102 K | $ 1.72 | - | $ 115 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
47.9 M | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
84.7 M | $ 1.09 | 2.83 % | $ 13.3 M | USA |